Search company, investor...

BioRelix

biorelix.com

Founded Year

2005

Stage

Series B - III | Dead

Total Raised

$35.36M

Last Raised

$270K

About BioRelix

BioRelix is discovering and developing new treatments for infectious diseases that target RiboSwitches, a class of RNA drug targets found in pathogenic bacteria and fungi. Riboswitches are short stretches of messenger ribonucleic acid (mRNA) that bind small molecules and control genes that are essential for the survival of many human pathogens. First identified in the laboratory of Prof. Ron Breaker at Yale University, several different classes of riboswitch mRNAs have been identified and each potentially could serve as a novel anti-infective drug target.

Headquarters Location

5 Science Park 401 Winchester Avenue

New Haven, Connecticut, 06511,

United States

203.785.9282

Missing: BioRelix's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: BioRelix's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest BioRelix News

BioRelix Inc. Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Dec 6, 2016

BioRelix, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 13:38 EST 6 Dec 2016 | BioPortfolio Reports Home » Topics » Alliances, mergers acquisitions and partnerships » Latest News » BioRelix, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' BioRelix, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by BioRelix, Inc. since January 2007. Key Findings Provides intelligence on BioRelix, Inc. MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by BioRelix, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for BioRelix, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about BioRelix, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

BioRelix Frequently Asked Questions (FAQ)

  • When was BioRelix founded?

    BioRelix was founded in 2005.

  • Where is BioRelix's headquarters?

    BioRelix's headquarters is located at 5 Science Park, New Haven.

  • What is BioRelix's latest funding round?

    BioRelix's latest funding round is Series B - III.

  • How much did BioRelix raise?

    BioRelix raised a total of $35.36M.

  • Who are the investors of BioRelix?

    Investors of BioRelix include Connecticut Innovations, Novartis Venture Funds, New Leaf Venture Partners, New Ventures at Yale University, CHL Medical Partners and 6 more.

  • Who are BioRelix's competitors?

    Competitors of BioRelix include Soteria Biotherapeutics, Catabasis Pharmaceuticals, CytImmune Sciences, Integral Molecular, Relypsa and 14 more.

Compare BioRelix to Competitors

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

S
SBIO Pte

SBIO is focused on the discovery and development of small molecule oncology drugs.

U
Unibioscreen

Unibioscreen is a specialist oncology discovery & development company, with focus on 'first in class' drugs, mainly of natural origin. Unibioscreen has successfully developed 2 drug candidates from discovery to clinical development in cancer patients and has other promising pre-clinical compounds in its pipeline.

P
Panacos Pharmaceuticals

Panacos is developing anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Per the company, Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.

K
KeyBay Pharma

KeyBay Pharma is dedicated to the discovery, development and commercialization of antibiotics.

C
CNSBio

Relevare Pharmaceuticals, formerly CNSBio, is a specialty pharmaceutical company focused on the development of novel therapies to treat chronic and acute pain. Relevare Pharmaceuticals exciting clinical-stage pipeline is comprised of programs that combine or reposition drugs known to be active at CNS targets that modulate pain perception and transmission, and for which there is strong safety evidence in humans. In April 2010, CNSBio rebranded to Relevare Pharmaceuticals.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.